Difengesic

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Difengesic

Difengesic is a synthetic pharmaceutical preparation containing the active ingredient Diclofenac, which is officially classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Its core function is to modulate the body's inflammatory response, providing both anti-inflammatory and analgesic (pain-relieving) benefits.

Property Description
Active ingredient Diclofenac (often as sodium or diethylammonium salt)
Form Tablet, Capsule, Suppository, Gel, Emulsion gel
Pharmacological class Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common purpose Relief of inflammation and mild to moderate pain
Origin Synthetic (Phenylacetic acid derivative)

Difengesic: Identity and Pharmacological Classification

Difengesic belongs to the chemical class of Phenylacetic acid derivatives, a group of synthetic compounds known for their established effects against pain and inflammation. As an NSAID, Diclofenac's primary mechanism involves restricting the production of prostaglandins, which are chemical messengers responsible for triggering the primary symptoms of swelling and pain. This specific mechanism is clinically recognized for its effectiveness in addressing chronic inflammatory conditions, such as those related to musculoskeletal discomfort. Diclofenac is a potent NSAID in the management of pain and inflammation, making it a reliable therapeutic option in its class.


Composition, Forms, and General Therapeutic Purpose

The active component in Difengesic is Diclofenac, frequently formulated as the salts Diclofenac sodium or Diclofenac diethylammonium. The medication is widely available in diverse forms, supporting varied therapeutic needs. This includes systemic preparations like tablets and capsules for internal use, and topical preparations such as gels and emulsion gels for external, localized application. This range of forms is a key differentiating factor, enabling either systemic relief throughout the body or focused action directly at the site of inflammation. Topical forms of Diclofenac are effective for local relief while often minimizing general systemic exposure, making them valuable for managing recent strains or localized rheumatic flare-ups. This flexibility ensures the general purpose of providing effective anti-inflammatory and pain relief remains achievable across different application methods.

Regulatory References

  1. Diclofenac - StatPearls - NCBI Bookshelf

What side effects are possible with Difengesic?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety-related restrictions for Difengesic, as established by government regulatory bodies.

Serious and Clinically Significant Risks

Official regulatory information identifies a risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. The risk may increase with higher doses and longer duration of use. Serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of the stomach or intestines, have also been documented. Additionally, cases of serious hepatotoxicity (severe liver injury) have been reported.

Adverse Reactions by Frequency

Adverse reactions are classified based on the frequency with which they have been observed in clinical data, including categories such as Very Common, Common, Uncommon, Rare, and Very Rare. Side effects are reported across several system-organ classes, including the gastrointestinal, nervous, cardiovascular, renal, and immune systems.

Safety Restrictions and Contraindications

Difengesic is subject to population-specific restrictions and limitations defined in regulatory documents. It is formally contraindicated (should not be used) in patients who have experienced allergic-type reactions to similar medicines, such as aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). It is also contraindicated in the setting of active or recent gastrointestinal bleeding and during the third trimester of pregnancy.

Exposure- and Duration-Related Patterns

Regulatory safety information emphasizes the relationship between medicine exposure and risk. The risk for serious cardiovascular and gastrointestinal adverse events may increase with higher dosage and prolonged duration of treatment. Official use context notes specify that the lowest effective dose for the shortest possible duration should be sought, and the medicine must be discontinued immediately if signs of serious adverse reactions occur.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Diclofenac (the active ingredient in Difengesic) details specific signs of overdose and mandates immediate emergency action.

Documented Manifestations and Severe Outcomes

An overdose may present with common manifestations such as nausea, vomiting (potentially with blood), epigastric pain, headache, drowsiness, confusion, and tinnitus (ringing in the ears).

However, regulators explicitly document the potential for severe, life-threatening outcomes, including acute renal failure, gastrointestinal bleeding and perforation, and serious central nervous system events such as seizures and coma, particularly in cases of massive ingestion.

The official labeling notes that no specific antidote is known for Diclofenac overdose. Management is therefore strictly confined to symptomatic and supportive treatment, which may include hospital monitoring, gastric lavage, activated charcoal, and the assessment of renal function.

When to Seek Immediate Medical Help

Regulatory instructions mandate that immediate medical attention must be sought for any suspected overdose event. This urgent action is required due to the risk of the documented severe systemic complications. Furthermore, elderly patients and those with pre-existing hepatic or renal impairment are noted to be at an increased risk for more serious complications in the event of an overdose.

Therapeutic Uses of Difengesic

What Difengesic Treats: Main Uses and Benefits

This medication is commonly used to help with symptoms related to physical discomfort and inflammatory or irritative states.

It is generally used in areas where short-term symptom management is appropriate, primarily to address pain, inflammation, swelling, and stiffness. This medication is relevant in contexts involving heightened systemic burden, in line with recognized therapeutic domains. It is applied in scenarios where additional management of discomfort is required, relevant to conditions presenting with systemic or localized discomfort, such as those that involve joint pain and stiffness.

It is commonly used to help manage symptoms related to conditions such as discomfort from muscle aches, sprains, menstrual cramps, certain types of headaches, and the stiffness associated with inflammatory joint conditions.

The supportive care it offers is relevant during acute episodes, providing symptomatic relief that helps patients cope more steadily with difficult periods. By being applied in addressing the swelling and stiffness caused by inflammation, it may assist with maintaining a sense of stability when symptoms are more noticeable and provides supportive relief when symptoms interfere with routine activities and movement.


Quick Fact: Relief for Joint Stiffness and Aches

This medication is relevant in conditions characterized by periods of heightened symptoms where symptoms may intensify temporarily, especially those that interfere with functional comfort in the joints.

Regulatory References

  1. FDA DailyMed documentation on Diclofenac Indications

Eligibility and Restrictions for Use

Eligibility Scope

Difengesic (Diclofenac), a Non-Steroidal Anti-Inflammatory Drug (NSAID), is generally approved for use in adults for systemic and topical formulations. Eligibility for use is strictly determined by the patient's existing health status, medical history, and age, as documented in regulatory labels.

Populations for whom use is contraindicated (must not use):

  • Patients with known hypersensitivity to Diclofenac, aspirin, or any other NSAID, or those with a history of asthma attacks, hives, or acute rhinitis following their use.
  • Patients with active gastrointestinal ulceration, bleeding, or perforation, or a history of recurrent peptic ulcer or hemorrhage.
  • Patients with severe hepatic failure or severe renal failure.
  • Patients with established congestive heart failure (NYHA Class II-IV), ischaemic heart disease, peripheral arterial disease, or cerebrovascular disease.
  • Patients in the setting of coronary artery bypass graft (CABG) surgery.
  • Women in the third trimester of pregnancy.

Age-Related and Condition-Specific Eligibility Rules

Classification Rule (Official Regulatory Statement)
Pediatric Use Systemic use is contraindicated in children typically below the age of one year. Topical gel is not recommended for children and adolescents under 14 years.
Older Adults Use is permitted but must be initiated with caution due to increased susceptibility to adverse effects like gastrointestinal bleeding and renal impairment.
Organ Impairment Mild to moderate hepatic or renal impairment generally requires use with caution or is not recommended.
Pregnancy/Lactation Use in the first and second trimesters is not recommended unless essential. Use during breastfeeding is not recommended.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formal Contraindicated Combinations and Restrictions

The most serious interaction-related restriction is the contraindication against combining Diclofenac (Difengesic) with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including analgesic doses of Aspirin. This combination presents a significant and additive risk of severe gastrointestinal events, such as bleeding and ulceration. Regulatory documents also prohibit the use of Diclofenac for the management of pain immediately following Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Drug Interactions

Combinations with anticoagulants (blood thinners) pose a substantial pharmacodynamic risk due to the enhanced potential for serious bleeding complications. Diclofenac interacts with certain antihypertensive agents (e.g., ACE Inhibitors, ARBs), which may diminish the blood pressure-lowering effect of those medicines and increase the risk of renal function deterioration. This renal risk is noted to be higher in the elderly or those with volume depletion.

Metabolic and Exposure-Altering Effects

Diclofenac is metabolized predominantly by the CYP2C9 enzyme. Co-administration with the strong inhibitor Voriconazole is documented to result in a quantified increase in Diclofenac's plasma exposure. Furthermore, Diclofenac reduces the renal clearance of substances such as Lithium and Methotrexate, which can lead to elevated plasma concentrations and potential toxicity of those co-administered agents. The official label also warns against the concurrent use of alcohol due to the increased risk of gastrointestinal toxicity.

Mechanism of Action

Primary Mechanism: Modulation of Prostaglandin Synthesis

Difengesic's primary action is the competitive inhibition of the Cyclooxygenase (COX) enzymes, specifically targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This molecular interaction restricts the conversion of Arachidonic Acid into Prostaglandins, which are key chemical messengers in physiological responses. The resulting reduction in localized Prostaglandin E2 ( PGE2) concentration decreases the excitability of peripheral nociceptors and contributes to the reduction of inflammatory mediators at the tissue level.

Dual Modulation of Nociceptive Signaling

The mechanism involves a dual influence on pain-related signaling. The peripheral action reduces the sensitization of nerve endings, while a secondary, non-COX activity modulates the Nitric Oxide (NO) system in the central nervous system. This combined action influences the transmission of afferent nociceptive signals, facilitating modulation within those pathways. The inherent, non-selective inhibition of COX-1 also limits the formation of cytoprotective prostaglandins within the gastrointestinal mucosa and suppresses Thromboxane A2 ( TXA2) in blood platelets.

Dosage and Administration Information

How Difengesic is Used: Administration Guidelines

The use of Difengesic (Diclofenac) is based on established protocols, emphasizing the lowest effective dose for the shortest necessary duration. Administration follows a standardized protocol based on the intended site of action.


Administration Scope and Form

Difengesic is available for administration via multiple routes. Systemic relief is achieved through oral forms (tablets, capsules, solutions), rectal forms (suppositories), or parenteral forms (intramuscular and intravenous injection). Localized relief is achieved through topical preparations, such as gels or emulsion gels. The dosage regimen is dependent on the formulation used.


Dosage and Frequency Patterns

Dosage follows specific numerical ranges. For chronic conditions, the typical systemic oral dose ranges from 100 mg to 150 mg daily, usually divided into two to four doses. The maximum daily systemic dose must not be exceeded. Parenteral use (IM/IV) is generally limited to a maximum of 150 mg daily and is not given for more than two consecutive days before transitioning to oral or rectal forms. Topical gels (1%) are applied four times daily.


Procedural and Contextual Requirements

Specific forms have strict intake rules. Oral powder packets, for instance, must be mixed with 1 to 2 ounces of plain water immediately before consumption and should be taken on an empty stomach. Conversely, enteric-coated tablets must be swallowed whole and must not be crushed, broken, or chewed to protect the coating. For topical administration, the gel must be applied only to intact skin and should not be covered with airtight occlusive dressings. Dosage adjustments for older adults require starting with the lowest available dose.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Research

Research has explored the use of the compound in individuals with chronic musculoskeletal pain, such as that associated with osteoarthritis. Studies evaluated whether administration was associated with changes in joint mobility and pain scores. Investigators examined the time course of changes in symptoms. In the studies, the compound was administered for durations of up to one year to determine long-term data. The research explored a general adult population.


Key Study Findings

Pain and Mobility Assessment

A multi-center, randomized, controlled trial (RCT) examined the compound's effects in participants with certain pain conditions.

  • Primary Outcome: The primary outcome of the trial was to track changes in pain intensity, typically measured by scales such as the Visual Analog Scale (VAS) at specific time points, including 4 and 8 weeks.
    • Finding: Researchers found that at 8 weeks, those who received the compound demonstrated a difference in average pain scores compared to the placebo group.
  • Secondary Outcome: Secondary outcomes included evaluating joint stiffness and physical function, often measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
    • Finding: The study reported that the WOMAC physical function subscale score was documented at the end of the study period.

Long-Term Follow-up and Safety

Long-term studies have explored administration of the compound for up to one year. Research has explored whether administration was associated with overall quality of life, using tools such as the SF-36 health survey. Data was collected on administration duration.

Study records documented the occurrence of adverse events, which are consolidated in the dedicated Safety and Side Effects section. Investigators concluded that the findings warrant additional investigation into the compound's therapeutic applications.

Frequently Asked Questions (FAQ)

Common questions about Difengesic (FAQ)

Q: How quickly is Difengesic expected to start working?

A: The time it takes for the medicine to start working can vary depending on the specific formulation being used. For immediate-release oral forms, the medicine typically reaches its highest levels in the bloodstream relatively quickly, often within an hour. However, formulations like enteric-coated tablets are designed to delay release, which means absorption may take longer to begin, as described in official product information.

Q: How long does the effect of a dose of Difengesic typically last?

A: The time the medicine remains in the bloodstream (its plasma half-life) is generally short, about 1 to 2 hours. However, to manage chronic conditions, official dosing regimens are typically designed to ensure the medicine is taken multiple times per day to achieve a desired therapeutic effect.

Q: What should be done if a dose of Difengesic is missed?

A: Official guidance on a missed dose typically indicates that if it is remembered soon after, the dose may be taken. If it is nearly time for the next scheduled dose, the missed one is generally skipped. Regulatory information advises against taking two doses at once to catch up, consistent with administration guidelines.

Q: Can people with kidney problems use Difengesic?

A: Regulatory documents indicate that the use of this medicine is associated with a risk of decreased kidney function. Because of this, caution is advised when it is prescribed to individuals who have pre-existing kidney conditions. Close monitoring of kidney function may be warranted during treatment.

Q: Does Difengesic have a sedative effect or cause drowsiness?

A: Official safety information lists certain effects on the central nervous system, such as dizziness and somnolence (drowsiness), as potential side effects. Caution regarding activities like driving or operating machinery is often advised in the official safety information due to the possibility of these effects.

Q: Are there any common foods or drinks that should be avoided when taking Difengesic?

A: The primary restriction mentioned in regulatory guidance is the concurrent use of alcohol, due to a documented increase in the risk of serious gastrointestinal events like stomach bleeding. Aside from specific instructions related to certain formulations, there are generally no warnings against common foods or drinks in the official product labeling.

Q: Is Difengesic safe for use in older adults?

A: Official safety data indicates that older adults are considered to be at a generally increased risk for severe adverse effects, particularly gastrointestinal bleeding and cardiovascular events. Regulatory guidance indicates that treatment in this population is often initiated with the lowest available effective dose.

Q: Is Difengesic approved for use in children or adolescents?

A: Whether the medicine is approved for use in children and adolescents depends on the specific illness being treated and the exact formulation. Where approved for pediatric use, official dosages are often calculated based on factors such as the child's weight, as detailed in the official product information.

Q: Can Difengesic affect blood pressure?

A: Official safety information documents that this medicine may be associated with the development of new high blood pressure (hypertension) or the worsening of pre-existing hypertension. Healthcare providers may recommend that blood pressure be monitored closely throughout the course of treatment.

Q: Are there long-term safety concerns with taking Difengesic regularly?

A: Regulatory warnings emphasize that the risk for serious side effects, including cardiovascular events (such as heart attack or stroke) and severe gastrointestinal events (like bleeding and ulcers), is stated to be associated with increased risk when higher dosages and prolonged duration of treatment are involved.

Q: What are the common signs of an allergic reaction to Difengesic?

A: Although uncommon, serious allergic reactions are noted in official safety documents. These reactions can involve symptoms such as the development of hives (urticaria), swelling of the face or throat (angioedema), and the worsening of asthma symptoms. Regulatory documents formally contraindicate (advise against) the use of this medicine in individuals who have a history of allergic reactions to other similar medicines.

Q: What does official research say about Difengesic for chronic conditions?

A: Official indications confirm that this medicine is approved for managing the signs and symptoms of specific chronic conditions, including rheumatoid arthritis and osteoarthritis, in the adult population. Research has focused on measuring changes in pain intensity and functional ability in these specific conditions, as noted in study overviews.

Q: Does Difengesic interact with birth control pills?

A: Regulatory documents indicate potential interactions with certain components found in oral contraceptives, such as drospirenone. The combination may lead to altered potassium levels in the blood, particularly in patients with existing risk factors like kidney impairment.

Q: What is the difference between the immediate-release and extended-release forms of Difengesic?

A: The distinction lies in how the medicine is delivered within the body. Extended-release formulations are specifically designed to release the active ingredient slowly over a longer time period. Immediate-release forms allow the medicine to be absorbed more quickly, according to pharmacokinetic data.

Q: Is Difengesic related to aspirin in how it works?

A: Yes, both Difengesic and aspirin belong to the pharmacological class known as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). They share a common mechanism of action by influencing the activity of cyclooxygenase (COX) enzymes in the body. The formal contraindication on their simultaneous use is noted in official documents.

Q: How is the recommended use of Difengesic generally described?

A: Official guidance consistently describes the recommended use according to a core principle: using the lowest effective dose for the shortest duration possible. This principle is emphasized to help minimize the potential risk of serious side effects on the cardiovascular and gastrointestinal systems.

Q: Is Difengesic commonly associated with skin reactions or rashes?

A: Official safety information includes the risk of both milder reactions like common rashes and itching, as well as the potential for serious skin reactions, which are rare but documented. These events are monitored and classified by their frequency in clinical data.

Q: Can Difengesic be used by people with a history of asthma?

A: The medicine is formally contraindicated in individuals who have a history of asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other NSAIDs. This is documented in the safety warnings.

Q: Is there information on Difengesic use during pregnancy in official sources?

A: Yes, official documents provide information on use during pregnancy, and it is formally contraindicated during the third trimester. Official guidance states that use during the first and second trimesters requires a careful assessment of benefits versus potential risks, as outlined in the product label.

Q: Can Difengesic be taken on an empty stomach?

A: The administration instructions depend entirely on the specific formulation. While some immediate-release oral forms may be specifically directed to be taken on an empty stomach, other common oral forms, such as enteric-coated tablets, have administration instructions that often involve taking them with food or milk, which may help reduce the possibility of stomach irritation.

Q: What is the official guidance on how Difengesic should be stored?

A: Official guidance advises that oral forms of the medicine should typically be stored at Controlled Room Temperature, which generally ranges between 20 C and 25 C (or 68 F and 77 F). The medicine should also be protected from excessive moisture and heat, as outlined in the official labeling.

Q: What should someone know about driving or operating machinery while taking Difengesic?

A: Official warnings are provided because the medicine may cause adverse effects like dizziness, drowsiness, or visual disturbances. Individuals who experience these effects are typically advised to exercise caution or avoid driving or operating complex machinery.

Q: What are the regulatory classifications for Difengesic?

A: Difengesic is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) based on its mechanism of action. Its specific regulatory status, such as whether it requires a prescription or is available over-the-counter, can vary by country and by the strength of the particular dose.

Q: Are there specific medical conditions that generally prevent someone from using Difengesic?

A: Yes, the official contraindications list certain conditions that formally prevent its use. These include having active or recent gastrointestinal bleeding, severe heart failure, or a history of allergic-type reactions to aspirin or other NSAIDs.

Q: What is the official definition of 'short-term use' for Difengesic?

A: While 'short-term' is a guiding principle, specific regulatory advisories exist for high-dose systemic use in patients with established cardiovascular disease, which may define a limit, such as no longer than four weeks. In all other cases, it refers to using the medicine for the absolute shortest duration necessary to achieve symptomatic relief.

Q: Can Difengesic be used to treat swelling or inflammation?

A: Yes, the medicine is officially indicated for conditions where it helps manage swelling and inflammation, in addition to pain. It is commonly used for conditions that involve inflammation, such as various forms of arthritis, as well as post-traumatic and post-operative inflammation.

Q: Is it safe to use Difengesic while breastfeeding, based on official information?

A: Official information generally suggests that only small amounts of the medicine pass into breast milk. Some regulatory sources classify its use during breastfeeding as acceptable, while also noting that alternative agents with more extensive data may be described in medical literature.

Q: How does the drug work to reduce discomfort, in simple terms?

A: In simple terms, the medicine works by blocking the production of natural substances in the body called prostaglandins. These prostaglandins are key chemical messengers that are responsible for causing signals of pain, fever, and inflammation. By reducing these messengers, the medicine helps lessen discomfort.

Q: Does Difengesic cause changes in mood or anxiety?

A: Official safety documents list psychiatric disturbances, including mood changes, as potential adverse reactions. These effects are typically reported as being less common or rare events, but they are recognized in the product information.

Q: Are there known interactions between Difengesic and herbal supplements?

A: General regulatory guidance often advises caution, as some herbal supplements may affect blood clotting or bleeding time, such as those containing ginkgo or garlic. Combining these with the medicine may increase the overall risk of bleeding.

Q: What are the official guidelines regarding maximum use duration for Difengesic?

A: The official guideline is to use the medicine for the shortest possible duration to manage symptoms. However, for high-dose systemic use in patients with certain established cardiovascular risk factors, specific maximum durations, such as no longer than four weeks, have been defined in safety advisories.

Q: Is Difengesic described as potentially affecting the liver?

A: Yes, official safety information documents a risk of serious hepatotoxicity, which is severe liver injury. Because of this, elevations of liver enzymes are a possibility, and monitoring of liver function may be advised during the course of treatment.

Q: How is Difengesic metabolized by the body, according to official sources?

A: Official pharmacokinetic information indicates that the medicine is primarily metabolized (broken down) in the liver. This process largely involves an enzyme system known as CYP2C9, as well as other metabolic pathways, before the medicine is prepared for elimination from the body.

Q: Are there specific instructions for disposing of unused Difengesic?

A: Official guidance for safe disposal often recommends that patients mix the medicine with an undesirable substance, such as dirt or used coffee grounds, and then place the mixture into a sealed bag for disposal in household trash. Alternatively, many pharmacies and communities offer formal drug take-back programs.

Q: What kind of pain is Difengesic most commonly used for?

A: According to the official indications, the medicine is commonly used to treat pain and inflammation associated with conditions such as osteoarthritis and rheumatoid arthritis. It is also indicated for managing pain that occurs following traumatic injuries or surgical procedures.

How should Difengesic be stored and disposed of?

Difengesic (Diclofenac) must be stored and disposed of according to specific requirements established in regulatory labeling to maintain stability and ensure safety.

Storage Requirements

Oral forms must be stored at Controlled Room Temperature, which is generally defined as 20 C to 25 C (68 F to 77 F), with protection from excessive moisture and heat. The medication must be kept in its original container or a tightly closed container to preserve product integrity.

All forms of Difengesic must be stored out of the sight and reach of children and pets.

Disposal Instructions

Used or expired Difengesic should be disposed of in accordance with local regulations for pharmaceutical waste. Used medicated patches, which retain drug residue, must be folded so the adhesive sides stick together before disposal to prevent accidental exposure.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Difengesic found in:

A-Z Index: